Germline genetic testing is essential in order to identify optimal treatments for patients with cancer, as well as detecting inherited mutations via cascade testing that could affect family members, according to John M.Carethers, MD, MACP, who emphasized that improvements to genetic testing technology and testing costs has increased not only the accuracy of, but access to these assays.
The technology in sequencing has moved from the old gels to capillary to ChIP [chromatin immunoprecipitation]-based, and has revolutionized the way we approached it. The depth of [genetic testing] coverage [has evolved], said Carethers. Sequencing technologies totally revolutionized this [process].
He added, There are some unusual situations in which additional technologies have to be used to figure out some of the ones that typical ChIP technologies don't fully explain. That has markedly changed the way we approach [testing] these days.
In an interview withOncLiveduring the 2020 Institutional Perspectives in Cancer (IPC) webinar on Precision Medicine, Carethers, a professor of Internal Medicine and Human Genetics at the University of Michigan, discussed recent developments in multi-gene panel testing.
OncLive: How are predictive and somatic genetic tests being utilized in clinical practice?
Carethers: In terms of germline testing, the benefit is knowing which disease you carry, and that information can also spread to other family members to understand whether they [are at an increased risk of getting a cancer diagnosis]. Sometimes, at least in my experience, [germline testing] does alleviate some anxiety. Some people get more anxious once they know they have a germline mutation, but in general, it does at least explain the reason why they're seeing certain diseases in the family. Thats the general benefit for germline testing.
The benefit of somatic testing is knowing the type of mutations that occur in the tumor; there may be a therapeutic drug or compound that is in current use that could benefit the patient. For instance, I had a patient with unresectable esophageal cancer. She was dying and her esophagus was almost completely obstructed with the tumor. She had a feeding tube put into her stomach and lost a lot of weight; she was literally counting out the days until she died. With some thought, we decided to take a sample of the tumor and do somatic testing.
She had some mutations that werent typically found in esophageal cancer, and we did have drugs [to treat her]. She was actually put on those drugs and the tumor shrunk dramatically to the point that she could eat again, she gained weight, and she lived another 5 years. Normally, she wouldn't have lasted more than a few months. The benefits of somatic testing is understanding the genetic makeup of the tumor in which you might be able to use some compounds that exist to benefit the patient. Thats the real goal of somatic testing.
There is an unusual situation for somatic testing, as well. For instance, in colon cancer, we know about Lynch syndrome, but there is also a Lynch-like syndrome. In Lynch-like syndrome, there is no germline [mutation], but the tumor has 2 somatic mutations of a mismatch repair deficient tumor. They can look like a Lynch syndrome tumor, and maybe even behave a little bit like a Lynch syndrome tumor, but they're really not caused by a germline mutation. Sometimes, somatic genetics can help us understand tumor genesis as well as ways to treat the tumor.
What changes have we seen recently in multigene panel testing? How are test results interpreted and how do they help guide treatment strategies?
There are patients who will walk in with the classic phenotype and then there are patients walking in who don't have the classic phenotype, yet they carry that mutation in the same gene. Multigene testing allows us to account for phenotypic variation.
Someone may walk in with colon cancer, the next person in the family might walk in with endometrial cancer, and the next person in the family may walk in with a skin tumor, but they all line up with the same mutation in Lynch syndrome. However, if you saw the skin tumor first, would you have thought of Lynch [syndrome]? [What about] if you saw the endometrium or the colon cancer? It depends on the specialty and the type of disease presentation they show up with. In many cases, though, the disease could be subtle.
For instance, there was a family I followed, which comprised the grandmother, mother, and daughter. The grandmother, who was well into her late 60s, had a Lynch syndrome mutation and got her colon removed appropriately. The mother was in her 40s with no cancers, but the daughter who was 21, developed colon cancer. It looked like it skipped a generation, yet, they all carry the same mutation. There's phenotypic variation, even with this exact same mutation in the family, because we're all genetically different to some, so there's probably modifiers and other things going on. However, if I can see that in this one family who I know [harbor that specific] mutation [then I know that] if multiple people walk into the clinic and have variations in their family histories and in their personal history of cancer, that we are seeing a wide phenotypic variation.
Now, instead of testing 1 gene at a time, we will test 30 or 50 genes at a time, and you can pick up some of these less penetrant genes that are causing the phenotypic variation. Sometimes there are major penetrant genes in these families.
What other barriers to germline testing need to be addressed?
We're always learning. Every year or so we add a few more genes to our repertoire and then, maybe they get on some of these panels. E3 ubiquitin ligase WWP1 is associated with PTEN hamartomatumorsyndrome, which is not on any panels, but the paper was published in the New England Journal of Medicine. We keep learning as we discover more and more of these genes. The more genes that we find tend to occur in less and less people, based on our current knowledge, but some of these patients present with these rare phenomena.
We're also finding out that some of these mutations arent specifically a change in the DNA sequencethere are methylation, or rearrangement, or even a deletion. You have to use other techniques in addition to sequencing to figure those families out or those families will be left in the lurch.
The downside of doing multigene panel testing is that now, if you push for more whole-exome and whole-genome sequencing, we have a lot more variants. One commercial lab got [results] back to me 2 months ago from a patient we had tested 4 years ago. They said, We finally have enough people [where we could determine that] his variant is not significant. It was good news. We are now more sure of variants because they now have more families in their database at the commercial lab. Sometimes it takes years to figure it out, unless we have functional analysis for all variants. Thats a big challenge right now.
Where do you hope to see the future of genetic testing head?
In a good way, genetic testing will probably [have a lower] cost and there [will be an] ease of doing it [with] whole-exome and whole-genome sequencing. It will even overtake panel testing over time because the machines are better and faster. The key, though, is having a database that you can go back and forth and analyze. Youre going to need the analytics and tools. What happens with the patient? Do I carry this [information] on a flash drive? Is it in a database I have to have access to?
It's not an easy answer and I'm not sure if the health system that a particular patient goes to is going to store all this information3 billion base pairs of informationand go back to it each time. Each place is going to have to have the right analytic tools to go back and [retrieve that information]. There are going to be some challenges with that, even though that's the way the technology is going.
The more challenging pieces [are related to] direct-to-consumer (DTC) testing. You don't always know what you're getting on those tests. We can test you for common diseases, such as diabetes and hypertension, but we also test you for BRCA1/2. In reality, very few of the DTC [tests] are doing sequencing or panel testing like we do clinically. Many of them are using single nucleotide polymorphisms (SNPs) that give you a suggestion. Many of these start from ancestry companies,and they recently moved into [testing for] these diseases because people are interested. I don't blame them for doing this, but the information they give might only [include] a fraction of the actual disease variants. If someone finds an SNP in BRCA1/2 or Lynch syndrome, you might need to see a doctor. [Based on your family history or phenotype,] we may have to send a ChIP test to verify [the results].
In some cases, people will test just to be curious, and they think they're going to have something, but there is zero evidenceno personal history and no family history. There are going to be some challenges with the DTC [testing] because we don't always know the type of test theyre getting and the information is not going to be as precise and could present challenges in the clinics. Some people are going to get upset because we're going to say, No, you don't need testing, or [patients will ask], Why does this test say I might have it but your test says I don't? We have to explain all this and those are going to be challenges.
What else would you like to add regarding the evolution of genetic testing?
There is phenotypic variability in the presentation of many of these syndromes. The standard now is multigenetic panel testing to try to assuage the phenotypic variation; we do pick up [genes in] people who we didn't necessarily think had that disease. I've been surprised too many times, so I'm not surprised anymore. A lot of these inherited conditions have phenotypic variability. If you have any suspicion or your primary care physician has any suspicion, feel free to send [a test] to our clinic because we can investigate that and do testing that's relatively cheap if there's a good cause to investigate that. It may save their life and the lives of their loved ones.
- Stress is a health hazard. But a supportive circle of friends can help undo the damaging effects on your DNA - The Conversation AU - November 22nd, 2021
- Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease -... - November 22nd, 2021
- Cracking the Cancer Code Requires Both Quiet and Chaos - OncLive - November 22nd, 2021
- Science Discovers Another Avenue That Could Lead to an HIV Cure - Yahoo News - November 22nd, 2021
- Alzheimer starts in the gut - Bangkok Post - November 22nd, 2021
- Letter to the Editor: Kyle Harper Responds to Monica H. Green - lareviewofbooks - November 22nd, 2021
- Penn Medicine Awarded $9.5 Million Grant from The Warren Alpert Foundation to Increase Diversity in Genetic Counseling Programs - pennmedicine.org - November 8th, 2021
- Is there a genetic component to heart disease? - Deccan Herald - November 8th, 2021
- Researchers investigate role of gene associated with Alzheimer's disease in brain's immune cells Indiana University School of Medicine - EurekAlert - November 8th, 2021
- NSU research scientist leads group that discovered gene variants that delimit HIV-1 infection - EurekAlert - November 8th, 2021
- Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics - Yahoo Finance - November 8th, 2021
- New technology sends Tufts veterinary scientists on journey to center of the cell - Tufts Daily - November 8th, 2021
- Hair colour: Maybe we're born with it. Maybe it's a melanin gene - National Post - November 8th, 2021
- More than 75% of Texans have COVID-19 antibodies, survey says - KHOU.com - November 8th, 2021
- Community Newsletter: Twitter dispatches from the American Society of Human Genetics annual meeting - Spectrum - October 28th, 2021
- Further and More Detailed Study of Domestic Cat Genome - JD Supra - October 28th, 2021
- MultiMuTHER Team Tracks Expression, Metabolite Relationships in Aging TwinsUK Participants - GenomeWeb - October 28th, 2021
- National Institutes of Health awards $1.65 million to University of Dayton researchers to study genetic basis of childhood diseases and birth defects... - October 28th, 2021
- Fortune and Great Place to Work Name Amgen One of the World's Best Workplaces in 2021 - PRNewswire - October 28th, 2021
- India holds a huge potential for driving the whole genomics industry: Tony Jose, Clevergene - ETHealthworld.com - October 28th, 2021
- 23andMe Honored in Fast Company's First Annual List of Brands That Matter - Marketscreener.com - October 28th, 2021
- A lucky few are unusually resistant to COVID-19. Scientists are trying to find a reason in their genes. - Mandurah Mail - October 28th, 2021
- Dr Aisha Pandor: How this award winning Human Genetics scientist developed an app to help keep your house clean - IOL - October 16th, 2021
- Popular theory of Native American origins debunked by genetics and skeletal biology - EurekAlert - October 16th, 2021
- 10 Surprising Facts About Birth Control (That You Probably Never Knew) - YourTango - October 16th, 2021
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 16th, 2021
- Bionano Genomics Announces ESHG Lineup Featuring 11 Customer Presentations of OGM Data Spanning Three Major Clinical Research Areas of Application... - August 31st, 2021
- Investing in the Power of Pathology and Genomics - Tufts Now - August 31st, 2021
- Humans are more than just a bag of genes - Commentary Box Sports - August 31st, 2021
- What Is the Most Important Scientific Development of the Last 50 Years? - Gizmodo Australia - August 31st, 2021
- 6 Greatest Breakthroughs in Agriculture that Changed the World - Krishi Jagran - August 31st, 2021
- Animal Expert Shares 5 Things That Will Help Your Dog Live a Longer, Healthier Life - ScienceAlert - August 31st, 2021
- Roman Catholics of Goa, Mangalore have early lineages of Brahmin community: Study - NewsMeter - August 31st, 2021
- The Poop About Your Gut Health and Personalized Nutrition - WIRED - August 31st, 2021
- Latest Research Strengthens Link Between Genetics and Suicidal Behaviors - University of Utah Health Care - July 21st, 2021
- Mixed-ancestry genetic research shows a bit of Native American DNA could reduce risk of Alzheimer's disease - The Conversation US - July 21st, 2021
- COVID-19 Roundup: The Unvaccinated Fuel Hospitalizations; Genetic Link to Severe Illness; and Children's Infection Rate - Baptist Health South Florida - July 21st, 2021
- Luck of the draw: How the random results of the genetic lottery can influence a host of your life's outcomes - Milwaukee Journal Sentinel - July 21st, 2021
- Kafer: The scary, promising and not too distant future of gene editing technology - The Denver Post - July 21st, 2021
- MUST READ OF THE WEEK: THE GENOME ODYSSEY BY DR EUAN ANGUS ASHLEY - Blackpool Gazette - July 21st, 2021
- Vence Bonham to be appointed acting NHGRI deputy director - National Human Genome Research Institute - June 6th, 2021
- UMaine researchers: Culture drives human evolution more than genetics - UMaine News - University of Maine - University of Maine - June 6th, 2021
- Myriad Genetics Recalibrates Breast Cancer PRS for All Ancestries in Anticipation of Broader Launch - Precision Oncology News - June 6th, 2021
- Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference - Yahoo Finance - June 6th, 2021
- Unprecedented Data Sharing Drives New Rare Disease Diagnoses Just Tip of the Iceberg - SciTechDaily - June 6th, 2021
- New Approach to DNA Research Could Be Key to Solving Mysteries of Deadly Diseases - University of Virginia - June 6th, 2021
- Critics of Alberta's new rules for supervised consumption sites say they will curb access for vulnerable clients - The Globe and Mail - June 6th, 2021
- The 'Wondrous Map': Charting of the Human Genome, 20 Years Later - Medscape - December 16th, 2020
- Neuron23 Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group - PRNewswire - December 16th, 2020
- Leading UK Core Labs Expand Investment in PacBio Sequencing Systems to Power Life Science Research with HiFi Reads - GlobeNewswire - December 16th, 2020
- Unique genetic factors and ancestry, along with lifestyle, influence skin cancer risk - Kaiser Permanente Division of Research - December 16th, 2020
- NIH's All of Us Research Program returns first genetic results to participants - National Institutes of Health - December 16th, 2020
- ONLINE: Wednesday Nite at the Lab - Isthmus - December 16th, 2020
- Researchers identify the origin of a deadly brain cancer - McGill Newsroom - December 16th, 2020
- Meet the MBA Class of 2022: Christopher Connolly, University of Michigan (Ross) - Poets&Quants - December 16th, 2020
- Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia... - December 16th, 2020
- Differences, Demonization, and DNA | Opinion - Harvard Crimson - November 17th, 2020
- Weekend reads: Inside one of Hollywood's most famous hotels amid the Covid-19 epidemic - The Daily Briefing - November 7th, 2020
- First Line Sequencing Seen as a Win for Both Parents and Doctors of Infants in ICU - Clinical OMICs News - November 7th, 2020
- Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionano's Optical Genome Mapping Technology Can Diagnose... - November 7th, 2020
- Experiencing happiness likely contributed to the dramatic growth and complexity of the human brain - Genetic Literacy Project - November 7th, 2020
- NIH researchers identify gene in mice that controls food cravings, desire to exercise - National Institutes of Health - November 7th, 2020
- Amgen To Present At The 29th Annual Credit Suisse Healthcare Conference - WFMZ Allentown - November 7th, 2020
- Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail's CEO - GlobeNewswire - November 7th, 2020
- ASHG 2020 Virtual Meeting to Showcase Innovative Research in Human Genetics - BioSpace - October 10th, 2020
- Evenings with Genetics discusses connection between cancer and genetics - Baylor College of Medicine News - October 10th, 2020
- Promoting global collaboration for brain health research - The BMJ - October 10th, 2020
- SKYMINT BRANDS -- Formerly Green Peak Innovations -- Joins Forces With DNA Genetics To Bring The World's Most Globally Awarded Flower Strains To... - October 10th, 2020
- U of T's Medicine by Design invests $1 million to advance new ideas in regenerative medicine - News@UofT - October 10th, 2020
- DCeased Proves Why Superboy Is the DC Universe's Gohan | CBR - CBR - Comic Book Resources - October 10th, 2020
- COVID-19 Shines Light on Disparities in Care for Patients With Cancer - OncLive - October 10th, 2020
- Genetic Study Uncovers Mutation Associated with Fibromuscular Dysplasia - University of Michigan Health System News - September 22nd, 2020
- Biopharm America: Of 'psychotic' behavior and term sheets in online dealmaking's brave new world - BioWorld Online - September 22nd, 2020
- 'It's all in the brain': The science behind stuttering - Genetic Literacy Project - September 22nd, 2020
- Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the 'Needle in the Haystack' Problem of Molecular Biology - Bio-IT World - September 22nd, 2020
- Sex is real - aeon.co - September 22nd, 2020
- Coronavirus mutations: what we've learned so far - The Conversation UK - September 22nd, 2020
- Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 billion deal - Metro US - September 22nd, 2020
- NeuBase Therapeutic's CEO, Dietrich A. Stephan, Ph.D., to Present at Tribe Public's Presentation and Q&A Webinar Event on August 26, 2020 - BioSpace - August 26th, 2020
- Canada Foundation for Innovation invests $9.3M in McGill highly-specialized research infrastructures - Science Business - August 26th, 2020